What question did this study set out to answer?

Summarize clinical outcomes and evaluate the therapeutic potential of claudin 18.2-targeted treatments in advanced gastric cancer.

January 1, 2020Chinese Journal of Cancer ResearchOpen Access

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer

View Full Paper

Ask AI

Bookmark

Summarize clinical outcomes and evaluate the therapeutic potential of claudin 18.2-targeted treatments in advanced gastric cancer.
Synthesized findings from clinical trials evaluating claudin 18.2 (CLDN18.2)-targeting agents, particularly zolbetuximab and cellular immunotherapies.
Assessed phase II trial data investigating zolbetuximab combined with epirubicin, oxaliplatin, and capecitabine (EOX) chemotherapy.
Combining zolbetuximab with EOX chemotherapy extended overall survival to 13.2 months with tolerable safety profiles in phase II testing.
Novel modalities including chimeric antigen receptor T-cell (CAR-T) immunotherapy present viable therapeutic strategies for CLDN18.2-positive gastric cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review demonstrates improved survival with claudin 18.2-targeted therapies in advanced gastric cancer, highlighting zolbetuximab as a promising therapeutic strategy.

Cite This Study

Zhang et al. (2020) studied this question.

synapsesocial.com/papers/6a03adcb28e1c76df7f01708 https://doi.org/10.21147/j.issn.1000-9604.2020.02.13

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates improved survival with claudin 18.2-targeted therapies in advanced gastric cancer, highlighting zolbetuximab as a promising therapeutic strategy.

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer

Key Points

Discussion

Implication

Cite This Study

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider